Nordea Investment Management AB Trims Holdings in Regeneron Pharmaceuticals, Inc. (REGN)
Nordea Investment Management AB trimmed its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 16.5% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 28,470 shares of the biopharmaceutical company’s stock after selling 5,634 shares during the quarter. Nordea Investment Management AB’s holdings in Regeneron Pharmaceuticals were worth $12,730,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also bought and sold shares of the company. Oppenheimer & Co. Inc. grew its holdings in Regeneron Pharmaceuticals by 20.6% during the 2nd quarter. Oppenheimer & Co. Inc. now owns 7,007 shares of the biopharmaceutical company’s stock worth $3,441,000 after acquiring an additional 1,199 shares during the last quarter. Dupont Capital Management Corp bought a new stake in Regeneron Pharmaceuticals during the 2nd quarter worth approximately $220,000. Shell Asset Management Co. grew its holdings in Regeneron Pharmaceuticals by 24.1% during the 3rd quarter. Shell Asset Management Co. now owns 15,435 shares of the biopharmaceutical company’s stock worth $5,565,000 after acquiring an additional 2,999 shares during the last quarter. Blair William & Co. IL grew its holdings in Regeneron Pharmaceuticals by 4.8% during the 2nd quarter. Blair William & Co. IL now owns 1,713 shares of the biopharmaceutical company’s stock worth $841,000 after acquiring an additional 79 shares during the last quarter. Finally, Principal Financial Group Inc. grew its holdings in Regeneron Pharmaceuticals by 2.4% during the 2nd quarter. Principal Financial Group Inc. now owns 115,201 shares of the biopharmaceutical company’s stock worth $56,580,000 after acquiring an additional 2,646 shares during the last quarter. 69.47% of the stock is currently owned by hedge funds and other institutional investors.
Regeneron Pharmaceuticals, Inc. (NASDAQ REGN) opened at $358.63 on Thursday. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.07 and a current ratio of 3.63. Regeneron Pharmaceuticals, Inc. has a 1 year low of $340.09 and a 1 year high of $543.55. The stock has a market cap of $39,322.68, a price-to-earnings ratio of 31.69, a P/E/G ratio of 1.44 and a beta of 1.56.
Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Wednesday, November 8th. The biopharmaceutical company reported $3.99 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.83 by $0.16. Regeneron Pharmaceuticals had a net margin of 23.17% and a return on equity of 25.73%. The company had revenue of $1.50 billion for the quarter, compared to the consensus estimate of $1.45 billion. During the same quarter in the previous year, the company earned $3.13 EPS. Regeneron Pharmaceuticals’s quarterly revenue was up 23.0% compared to the same quarter last year. research analysts expect that Regeneron Pharmaceuticals, Inc. will post 13.55 earnings per share for the current fiscal year.
In related news, CFO Robert E. Landry sold 189 shares of the business’s stock in a transaction on Tuesday, September 5th. The shares were sold at an average price of $501.06, for a total transaction of $94,700.34. Following the transaction, the chief financial officer now owns 10,099 shares in the company, valued at approximately $5,060,204.94. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Robert E. Landry sold 663 shares of the business’s stock in a transaction on Wednesday, September 6th. The shares were sold at an average price of $498.60, for a total transaction of $330,571.80. Following the transaction, the senior vice president now owns 10,099 shares in the company, valued at approximately $5,035,361.40. The disclosure for this sale can be found here. Insiders have sold a total of 4,352 shares of company stock worth $2,037,772 in the last quarter. 10.80% of the stock is owned by corporate insiders.
A number of equities research analysts have weighed in on the stock. Morgan Stanley reissued an “equal weight” rating and set a $450.00 target price on shares of Regeneron Pharmaceuticals in a report on Wednesday, August 23rd. Canaccord Genuity reissued a “buy” rating on shares of Regeneron Pharmaceuticals in a report on Monday, October 16th. Barclays lowered shares of Regeneron Pharmaceuticals from an “equal weight” rating to an “underweight” rating and reduced their target price for the stock from $450.00 to $395.00 in a report on Friday, October 20th. Oppenheimer reaffirmed a “hold” rating on shares of Regeneron Pharmaceuticals in a research note on Wednesday, September 27th. Finally, Leerink Swann reaffirmed an “outperform” rating and issued a $580.00 price objective (up from $573.00) on shares of Regeneron Pharmaceuticals in a research note on Wednesday, August 9th. Two equities research analysts have rated the stock with a sell rating, fifteen have given a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $471.69.
TRADEMARK VIOLATION WARNING: “Nordea Investment Management AB Trims Holdings in Regeneron Pharmaceuticals, Inc. (REGN)” was reported by Daily Political and is the property of of Daily Political. If you are accessing this story on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this story can be read at https://www.dailypolitical.com/2017/11/30/nordea-investment-management-ab-trims-holdings-in-regeneron-pharmaceuticals-inc-regn.html.
Regeneron Pharmaceuticals Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.